NGM 282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial-Reference-Cited by-同舟云学术

NGM 282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial

Published:2018-08-30 Issue:9 Volume:2 Page:1037-1050
ISSN:2471-254X
Container-title:Hepatology Communications
language:en
Short-container-title:Hepatology Communications

Author:

Mayo Marlyn J.¹,Wigg Alan J.²,Leggett Barbara A.³,Arnold Hays⁴,Thompson Alexander J.⁵,Weltman Martin⁶,Carey Elizabeth J.⁷,Muir Andrew J.⁸,Ling Lei⁹,Rossi Stephen J.⁹,DePaoli Alex M.⁹

Affiliation:

1. University of TexasSouthwestern Medical CenterDallasTexas

2. Flinders Medical CenterAdelaideSouth AustraliaAustralia

3. Royal Brisbane and Women's Hospital and School of MedicineUniversity of QueenslandBrisbaneQueenslandAustralia

4. Digestive Research CenterSan AntonioTexas

5. St. Vincent's HospitalMelbourneVICAustralia

6. Nepean HospitalSydneyNew South WalesAustralia

7. Mayo Clinic–ArizonaScottsdaleArizona

8. Duke UniversityDurhamNorth Carolina

9. NGM Biopharmaceuticals Inc.South San FranciscoCalifornia

Funder

NGM Biopharmaceuticals

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep4.1209

Reference34 articles.

1. Primary biliary cirrhosis

2. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis

3. Primary biliary cirrhosis

4. Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study

5. New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials;Expert Opinion on Emerging Drugs;2024-07-04

2. The endocrine FGFs axis: A systemic anti-fibrotic response that could prevent pulmonary fibrogenesis?;Pharmacology & Therapeutics;2024-07

3. Silibinin, a commonly used therapeutic agent for non‐alcohol fatty liver disease, functions through upregulating intestinal expression of fibroblast growth factor 15/19;British Journal of Pharmacology;2024-06-05

4. Serum bile acid change correlates with improvement in pruritus in patients with primary biliary cholangitis receiving linerixibat;Liver International;2024-05-23

5. Progress in the Management of Patients with Cholestatic Liver Disease: Where Are We and Where Are We Going?;Journal of Clinical and Translational Hepatology;2024-05-11